SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending after releasing positive interim results from a pivotal trial for its ANKTIVA bladder cancer treatment, indicating superior efficacy for first-line use, as the community discusses its transformative market potential and significant short interest, alongside strategic moves by its founder into radioligand therapy supply.

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

Incannex Healthcare Inc

Incannex Healthcare Limited - ADR

Incannex Healthcare is trending due to a recently enacted 1-for-30 reverse stock split, which has sparked intense debate among investors. While many view the move as a sign of management's incompetence and predict further dilution, others believe it strategically cleans up the capital structure, enables Nasdaq compliance, and positions the company for significant catalysts, including its de-risked and Fast-Tracked drug pipeline.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is rallying as the community intently focuses on whether the company will decline to match a recently deemed superior offer for Warner Bros. Discovery, with many investors hoping this avoids substantial debt and regulatory obstacles, potentially triggering further upside as the crucial decision looms.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is trending as a major strategic shift towards AI and high-performance computing data centers, driven by new partnerships and acquisitions, is generating intense community discussion and speculation about a significant short squeeze, largely overshadowing recent disappointing financial results.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending after its latest earnings report revealed record annual revenue, a GAAP profit, and robust 2026 guidance, sparking strong bullish sentiment among investors. The community is actively debating the potential for a short squeeze given high short interest, though some members remain cautious about the company's long-term profitability trajectory.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is trending as its WVE-007 obesity treatment garners significant community excitement for its differentiated profile, showing fat loss with muscle preservation and potential for infrequent dosing, especially following recent setbacks for competing GLP-1 therapies. Analysts and investors are closely watching upcoming presentations and financial results, fueling M&A speculation for its innovative RNAi platform in a rapidly expanding market.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending as Netflix walks away from its acquisition bid after Paramount Skydance's offer was deemed superior, with the community largely praising Netflix's strategic move to collect a significant breakup fee, while WBD investors anticipate a higher payout from Paramount despite new debt concerns for the acquirer.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab's Q4 earnings report is driving conversation with strong revenue growth and backlog, though the Neutron rocket's first launch is now targeted for late 2026. Community discussion highlights numerous new launch contracts and strategic acquisitions, particularly strengthening RKLB's position in the defense sector and solidifying its role as a diversified space systems provider.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is trending due to the final investment approval for its Romanian SMR project, bolstering the narrative that small modular reactors are essential for increasing global power demands, especially from AI data centers. The community is actively debating this positive catalyst against recent selling pressure from a major shareholder and ongoing class-action lawsuit allegations, leading to high volatility.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide (WRD) is trending on the heels of robust Q3 earnings, expanded global robotaxi services with Uber, and its upcoming inclusion in the Hang Seng Composite Index. The community is intensely debating whether these operational milestones and increasing institutional accumulation by firms like ARK Invest will finally trigger a significant market re-evaluation of its leadership in the autonomous driving sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company issues FY26 revenue guidance of $720 million-$760 million and Q1 guidance of $135 million-$155 million, both below consensus estimates.</li><li>Naloxone nasal spray revenues fell 41% due to rising competition, while anthrax biodefense product revenues rose 64% on delivery timing.</li><li>The company also announced new Canadian contracts worth up to C$140 million.</li></ul>Shares of Emergent BioSolutions, Inc. (EBS) fell over 20% in extended trading on Thursday after the company issued weaker-than-expected financial guidance for both the first quarter and full year 2026, overshadowing contract wins and a new stock buyback program.<a href="https://stocktwits.com/symbol/EBS">EBS stock</a> rose 0.8% in Thursday’s regular session.<h2 class="st-heading-2">Weak Outlook Weighs On Sentiment</h2>The biodefense company forecast full-year 2026 revenue in the range of $720 million to $760 million, below analysts’ consensus estimate of $809.4 million. The company also guided for first-quarter revenue of $135 million to $155 million, significantly below consensus expectations of $275 million.It also projected adjusted net income between $25 million and $45 million, and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $135 million to $155 million."Our team remains focused on long-term sustainable value and achieving our vision of enabling several durable and profitable verticals in the Company over time," said CEO Joe Papa.<h2 class="st-heading-2">Earnings Miss Adds Pressure</h2>The cautious outlook came alongside weaker quarterly performance. Emergent reported a fourth-quarter (Q4) loss of $0.43 per share, compared with earnings of $0.05 per share a year earlier. Revenue came in at $148.7 million, missing expectations of $217.5 million.Naloxone product revenues from its opioid overdose reversal nasal sprays declined 41% due to increased competition. Anthrax medical countermeasure revenues, which include vaccines and treatments used for biodefense preparedness, rose 64%, driven by the timing of delivery. "Emergent's 2025 results demonstrate significant progress executing our multi-year turnaround strategy, delivering improved operating margins, strong adjusted EBITDA of $205 million, increased cash flow and lower leverage," Papa said.<h2 class="st-heading-2">Positive Developments Fail To Offset Concerns</h2>The company also announced new agreements worth up to C$140 million with the Canadian government agencies to supply medical countermeasures for biological threat preparedness. Emergent expects to receive more than C$35 million in orders from these contracts this year.Separately, the board authorized a new $50 million share repurchase program running through March 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for EBS was ‘extremely bullish’ amid a 285% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/ebs_ss_png_5927fdd04b.webp" alt="ebs ss.png" width="976" height="140"><figcaption>EBS sentiment and message volume as of February 27 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/ComradeKomisar/message/646069727">said</a>, “Pretty sure they 'sand bagged' the guidance, like they always do, and that order either will repeat, or we'll get it from Canada which can be threatned to lose the Winnipeg site, and move it to the US.”<stembedurl>https://stocktwits.com/ComradeKomisar/message/646069727</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Kawasaki1/message/646066600">said</a>, “Up 50 cents/ since the over reaction earlier...We were undervalued going into earnings and the future is still promising”<stembedurl>https://stocktwits.com/Kawasaki1/message/646066600</stembedurl>EBS stock has declined 10% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the Emergent BioSolutions logo of an US biopharmaceutical company is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today?

The board authorized a new $50 million share repurchase program running through March 2027.

Equity

Emergent Biosolutions (NYSE:EBS) Releases Quarterly Earnings Results

Emergent Biosolutions (NYSE:EBS - Get Free Report) released its earnings results on Thursday. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing...

Emergent Biosolutions (EBS) Expected to Announce Earnings on Monday

Emergent Biosolutions (NYSE:EBS) will be releasing its Q4 2025 earnings after the market closes on Monday, March 2. (View Earnings Report at...

Emergent Biosolutions Inc. $EBS Shares Purchased by Allianz Asset Management GmbH

Allianz Asset Management GmbH grew its stake in shares of Emergent Biosolutions Inc. (NYSE:EBS - Free Report) by 149.0% during the 3rd quarter, according to the company in its most recent Form 13F...

New York State Common Retirement Fund Has $4.60 Million Stock Holdings in Emergent Biosolutions Inc. $EBS

New York State Common Retirement Fund lifted its stake in shares of Emergent Biosolutions Inc. (NYSE:EBS - Free Report) by 32.6% in the third quarter, according to its most recent Form 13F filing...

Emergent Biosolutions (NYSE:EBS) Share Price Passes Above 200-Day Moving Average - Here's Why

Emergent Biosolutions (NYSE:EBS) Share Price Passes Above 200-Day Moving Average - Should You Sell...

<ul class="summary-bullets"><li>The Attorney General’s lawsuit alleges that Kramer knew about the manufacturing and contamination issues and yet executed a trading plan before those issues were made public in violation of the law.</li><li>James is now seeking damages, disgorgement, and costs from Kramer.</li><li>Emergent inked contracts worth $261 million with AstraZeneca in 2020 to manufacture the latter’s Covid-19 vaccine.</li></ul>Shares of Emergent Biosolutions Inc (EBS) slumped 13% on Thursday after New York State Attorney General Letitia James sued the company’s former CEO Robert G. Kramer for insider trading.James also inked a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ag.ny.gov/press-release/2026/attorney-general-james-sues-former-ceo-emergent-biosolutions-insider-trading">settlement</a> with Emergent under which the company will pay $900,000 in penalties for approving Kramer’s trading plan. Emergent will improve its executive trading policies, James said.<h2 class="st-heading-2">Transactions In Question</h2>Emergent inked contracts worth $261 million with AstraZeneca in 2020 to manufacture the latter’s Covid-19 vaccine. However, large amounts of the vaccines Emergent produced were contaminated, rendering them unusable.According to a probe by the Office of the Attorney General, Kramer was made aware of the contamination in October 2020 and the company omitted the unresolved contamination issues in communications through November. It instead approved Kramer’s trading plan under which he sold his company shares for over $10 billion, James said, while adding that Emergent's shares began to drop shortly after Kramer completed his sales in February 2021.The U.S. Food and Drug Administration (FDA) ordered a permanent halt to Emergent’s production of the AstraZeneca (AZN) vaccine in April 2021. The Attorney General’s lawsuit alleges that Kramer knew about the manufacturing and contamination issues and executed a trading plan before those issues were made public in violation of the law. James is now seeking damages, disgorgement, and costs from Kramer.“At the height of the COVID-19 pandemic, Robert Kramer illegally profited millions by selling his company shares, while knowing that Emergent faced issues producing the AstraZeneca vaccine for millions of people. Kramer’s actions were illegal and unethical, and we are holding him accountable,” James said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around EBS rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user dismissed the penalty amount as irrelevant to the company’s financials.<stembedurl>https://www.stocktwits.com/KnuckleSandwich/message/641972166</stembedurl>Another termed the sell-off an “easy buying opportunity.”<stembedurl>https://www.stocktwits.com/AlarmedSheiky/message/641962084</stembedurl><a href="https://stocktwits.com/symbol/EBS">EBS stock</a> has gained 15% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-continues-rally-on-preliminary-revenue-numbers/cmU1wPAR4Jh">IBRX Stock Continues Rally — What’s Driving The Optimism Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The exterior view of the Emergent BioSolutions plant on April 01, 2021 in Baltimore, Maryland. (Photo by Tasos Katopodis/Getty Images)

Why Did EBS Stock Fall 13% Today?

New York State Attorney General Letitia James inked a settlement with Emergent under which the company will pay $900,000 in penalties. 

Emergent Biosolutions Stock Plummets Amid Insider Trading Allegations Against Former CEO

New York State Attorney General Letitia James inked a settlement with Emergent under which the company will pay $900,000 in penalties. 


Emergent Biosolutions (NYSE:EBS) Stock Price Down 7.4% - What's Next?

Emergent Biosolutions (NYSE:EBS) Stock Price Down 7.4% - Time to Sell...

Emergent Biosolutions (NYSE:EBS) Reaches New 52-Week High - Time to Buy?

Emergent Biosolutions (NYSE:EBS) Hits New 52-Week High - Time to Buy...

Silver Oak Securities Incorporated Purchases New Position in Emergent Biosolutions Inc. $EBS

Silver Oak Securities Incorporated purchased a new stake in Emergent Biosolutions Inc. (NYSE:EBS - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities...

$EBS Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of -$1.04 down -79.31% YoY
• Reported revenue of $148.7M down -23.63% YoY
• Emergent forecasts full year 2026 total revenues between $720M, adjusted net income of $25M, and adjusted EBITDA of $135M, with total adjusted gross margin % projected at 45%-47%.

Stocktwits

Emergent Biosolutions Inc

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of -$1.04 down -79.31% YoY
• Reported revenue of $148.7M down -23.63% YoY
• Emergent forecasts full year 2026 total revenues between $720M, adjusted net income of $25M, and adjusted EBITDA of $135M, with total adjusted gross margin % projected at 45%-47%.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Traders are reacting strongly to the Q4 2025 earnings and 2026 revenue guidance, citing a larger than expected net loss and flat outlook, leading to a significant dip.

A significant short interest, estimated at 17% or higher, has traders anticipating a potential short squeeze despite recent bearish price action.

New multi-product contracts from the Canadian government, valued at approximately $140 million CAD, highlight the company's ongoing role in medical countermeasures.

Speculation persists that the company may be an attractive acquisition target for larger pharmaceutical or private equity firms given its cash flow and recent valuation dip.

The company's announcement of a new $50 million stock repurchase program is seen by some as a potential catalyst and a sign of corporate confidence.

EBS
Emergent Biosolutions Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Earnings Recap

Latest EBS News

EBSEmergent Biosolutions Inc